Ensho Therapeutics

Ensho, which means inflammation, flame, or glow in Japanese, reflects our strong desire to provide breakthrough oral therapies for patients with inflammatory diseases. We believe that our pipeline of oral small-molecule integrin α4β7 inhibitors will bring transformative change to patients with inflammatory bowel disease (IBD). In the first half of 2025, we plan to initiate the Phase 2 clinical program for our lead candidate NSHO-101 (also known as EA1080). We are confident that we can offer an oral treatment option for α4β7 inhibition—a mechanism proven safe and effective by a commercially available antibody but currently lacking an oral alternative. For millions of IBD patients, we aim to eliminate their inflammation and alleviate this difficult-to-treat condition.